Browse by author
Lookup NU author(s): Emerita Professor Alison Tyson-Capper, Dr Philip Hyde, Emeritus Professor John Kirby
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Total joint replacement (TJR) is indicated for patients with end-stage osteoarthritis (OA) where conservative treatment has failed. Approximately 1.3 million primary hip replacement surgeries have been recorded in the United Kingdom since 2003 and this number is set to rise due to an increase in obesity as well as an ageing population. Total hip replacement (THR) has a survival rate of 85% at 20 years; the most common reason for failure is aseptic loosening which often occurs secondary to osteolysis caused by immune-mediated inflammation responses to wear debris generated from the materials used in the THR implant. Therefore, by understanding the biological steps by which biomaterials cause immune-mediated reactions it should be possible to prevent them in the future thereby reducing the number of costly revision surgeries required.
Author(s): Shannon J, Tyson-Capper A, Hyde P, Kirby J
Publication type: Conference Proceedings (inc. Abstract)
Publication status: Published
Conference Name: 29th Annual Meeting of the European Orthopaedic Research Society (EORS)
Year of Conference: 2021
Pages: 10-10
Print publication date: 01/11/2021
Online publication date: 01/11/2021
Acceptance date: 01/11/2021
Publisher: British Editorial Society of Bone & Joint Surgery
URL: https://doi.org/10.1302/1358-992X.2021.13.010
DOI: 10.1302/1358-992X.2021.13.010
Series Title: Orthopaedic Proceedings
